Reply

Jonathan G Stine^{1

2

3

4}, Ian R Schreibman^{1

3}, Alison J Faust^{1

3}, Jessica Dahmus¹, Benjamin Stern¹, Christopher Soriano¹, Gloriany Rivas¹, Breianna Hummer¹, Scot R Kimball⁵, Nathaniel R Geyer², Vernon M Chinchilli², Kathryn Schmitz^{2

4

6

7}, Christopher Sciamanna^{2

4

8}

Affiliations

¹ Division of Gastroenterology and Hepatology, Department of Medicine, The Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
² Department of Public Health Sciences, The Pennsylvania State University-College of Medicine, Hershey, Pennsylvania, USA.
³ Liver Center, The Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
⁴ Cancer Institute, The Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
⁵ Department of Physiology, The Pennsylvania State University-College of Medicine, Hershey, Pennsylvania, USA.
⁶ Department of Kinesiology, The Pennsylvania State University-College of Medicine, Hershey, Pennsylvania, USA.
⁷ Department of Physical Medicine & Rehabilitation, The Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
⁸ Department of Medicine, The Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.

Jonathan G Stine et al. Hepatology. 2022 Jul.

. 2022 Jul;76(1):E18-E19.

doi: 10.1002/hep.32390. Epub 2022 Mar 9.

¹ Division of Gastroenterology and Hepatology, Department of Medicine, The Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
² Department of Public Health Sciences, The Pennsylvania State University-College of Medicine, Hershey, Pennsylvania, USA.
³ Liver Center, The Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
⁴ Cancer Institute, The Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
⁵ Department of Physiology, The Pennsylvania State University-College of Medicine, Hershey, Pennsylvania, USA.
⁶ Department of Kinesiology, The Pennsylvania State University-College of Medicine, Hershey, Pennsylvania, USA.
⁷ Department of Physical Medicine & Rehabilitation, The Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
⁸ Department of Medicine, The Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.

No abstract available

Conflict of interest statement

CONFLICT OF INTEREST

Dr. Stine received grants from Novo Nordisk, Noom, Inc., AstraZeneca and Grifols.

NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH.
Stine JG, Schreibman IR, Faust AJ, Dahmus J, Stern B, Soriano C, Rivas G, Hummer B, Kimball SR, Geyer NR, Chinchilli VM, Loomba R, Schmitz K, Sciamanna C. Stine JG, et al. Hepatology. 2022 Jul;76(1):172-185. doi: 10.1002/hep.32274. Epub 2022 Jan 22. Hepatology. 2022. PMID: 34890063 Free PMC article. Clinical Trial.
Letter to the editor: Is PAI-1 a thrombotic biomarker in NASH cirrhosis?
Zanetto A, Campello E, Spiezia L, Burra P, Simioni P, Senzolo M. Zanetto A, et al. Hepatology. 2022 Jul;76(1):E16-E17. doi: 10.1002/hep.32392. Epub 2022 Feb 17. Hepatology. 2022. PMID: 35112379 No abstract available.

1. Stine JG, Schreibman IR, Faust AJ, Dahmus J, Stern B, Soriano C, et al. NASHFit: a randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH. Hepatology. 2022;76:172–85. - PMC - PubMed
1. Stine JG, Shah NL, Argo CK, Pelletier SJ, Caldwell SH, Northup PG. Increased risk of portal vein thrombosis in patients with cirrhosis due to non-alcoholic steatohepatitis (NASH). Liver Transpl. 2015;21:1016–21. - PMC - PubMed
1. Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, Zoppini G, et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring). 2008;16:1394–9. - PubMed
1. Rivas G, Hummer-Bair B, Bezinover D, Kadry Z, Stine J. Plasminogen activator inhibitor is significantly elevated in liver transplant recipients with decompensated NASH cirrhosis. BMJ Open Gastroenterol. 2021;8:e000683. - PMC - PubMed